iberdomide (CC-220)

P1/2, N=66, Recruiting, Hackensack Meridian Health | Trial completion date: Nov 2025 --> May 2026 | Trial primary completion date: Nov 2025 --> May 2026

P1, N=121, Recruiting, Hoffmann-La Roche | Trial completion date: Mar 2029 --> Sep 2029 | Trial primary completion date: Mar 2027 --> Sep 2029

P1/2, N=49, Active, not recruiting, Mayo Clinic | Trial primary completion date: May 2027 --> Mar 2026

P1/2, N=49, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting

P2, N=68, Recruiting, Emory University | Trial completion date: Oct 2025 --> Sep 2029 | Trial primary completion date: Sep 2025 --> Sep 2027

P1/2, N=21, Terminated, Celgene | Completed --> Terminated; Business objectives have changed

P1, N=135, Recruiting, AbbVie | Trial completion date: Jan 2037 --> Mar 2036

P1/2, N=200, Recruiting, Hoffmann-La Roche | Trial completion date: May 2027 --> Jul 2028 | Trial primary completion date: May 2027 --> Jul 2028

The addition of anti-PD1 and pomalidomide reduced the T cell exhaustion that occurs in response to TCE in high tumor burden settings. This was accompanied by more favorable T cell profiling, with limited expansion of regulatory T cells and exhaustion. In total, administering TCE following dexamethasone and iberdomide treatments provided deeper and more durable responses with reduced risk of CRS.

P1, N=135, Recruiting, TeneoOne Inc. | Trial primary completion date: Jun 2036 --> Mar 2036

Building on the success of immunomodulatory agents, CRBN E3 ligase modulators (CELMoDs), iberdomide (CC-220) and mezigdomide (CC-92480), have been designed as promising and more selective agents. Combining CELMoDs with cellular therapies significantly improves the response rate in MM patients. In this paper, based on the literature presented at the Annual Meeting of the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the International Myeloma Society (IMS), and the European Hematology Association (EHA) in the 2020-2025 timeframe, we explore the rationale and emerging evidence of combining CELMoDs with immunotherapies, and their use as a bridge to transplant or as post-ASCT maintenance therapy in MM.

An isogenic subline of MM.1S cells with acquired lenalidomide resistance remains sensitive to GCK inhibition-induced IKZF1/3 downregulation and cell growth inhibition. These findings underscore GCK as a promising therapeutic target for bypassing IMiD resistance in MM. Combining GCK inhibition with iberdomide could provide a novel strategy to manage relapsed or refractory patients with multidrug resistance, especially after the exhaustion of immunotherapy.